Obesity Archives - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

Lilly and Resilience Invest $750M to Expand Medicine Production in Ohio

August 10, 2026

Optimize Obesity Development: Endpoint Strategies for Early-phase Innovation to Late-phase Differentiation

September 17, 2026

Obesity and MASH Drug Development: What Comes After Weight Loss?

Beyond Weight Loss: Obesity Trial Design for Real-World Patient and Payer Impact

Life Science Podcast

What’s Next in Obesity and MASH Clinical Research with MetaVia’s Hyung Heon Kim — Episode 258

Novo Nordisk Canada Moves to Keep Ozempic Affordable for Some Uninsured Patients

10 Obesity Drug Companies to Watch in 2026

iBio’s Global Clinical Trial Strategy for Advancing Next-Gen Obesity Drugs

GLP-1 Candidate Survodutide Shows Strong Weight Loss Results in Phase III Trials

Kailera Therapeutics IPO Raises $718.8M for Obesity Drug Pipeline

Retatrutide vs. Zepbound: How Does Lilly’s Next-Gen Obesity Drug Compare to Tirzepatide?

Apotex Leads Race for Generic Ozempic with Tentative FDA Approval

Foundayo (Orforglipron) Approval Adds Momentum in the Oral GLP-1 Space Against Rival Wegovy

Novo Nordisk and Hims & Hers Bury the Hatchet and Partner to Expand Access to Ozempic, Wegovy

Wegovy HD Receives FDA Approval as Fourth Product Under National Priority Voucher Program

Lilly’s Retatrutide Shows Promising A1C and Weight Reductions in First Diabetes Trial

Next Page »